The move will allow the Canadian antibody discovery firm to woo more US investors and boost its liquidity.
“As ImmunoPrecise gains recognition for its best-in-class full-service, therapeutic antibody discovery company, we are experiencing increased interest from investors across North America and other International markets,” said Lisa Hebling, chief financial officer.
READ: ImmunoPrecise Antibodies shares up as it launches new antibody discovery platform with US pharma group
"Our listing on the OTCQB allows for better access to the U.S. investment community, greater international visibility, and improved liquidity," Hebling added.
The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.
The company’s attention is fixed on discovering and delivering the most relevant next-generation antibodies, with the highest probability of succeeding through clinical validation.
It recently opened a new office in Cambridge, Massachusetts that will be staffed at first for sales and business development and will take advantage of the Cambridge area’s focus on biotech and pharmaceuticals.
ImmunoPrecise closed at US$0.58 in New York on Wednesday.
Contact Ellen Kelleher at [email protected]